Abstract | BACKGROUND: METHODS: Full-thickness porcine wounds were infected with Staphylococcus aureus. Using polyurethane wound enclosure devices, wounds were treated with topical 100 μg/ml minocycline, topical 1000 μg/ml minocycline, topical saline control, or 4 mg/kg intravenous minocycline. Bacteria were quantified in wound tissue and fluid obtained over 9 hours. Immunosorbent assays were used to analyze inflammatory marker concentrations. Minocycline's effect on in vitro migration and proliferation of human keratinocytes and fibroblasts was tested using scratch assays and metabolic assays, respectively. RESULTS: After 6 hours, 100 and 1000 μg/ml topical minocycline decreased bacteria in wound tissue to 3.5 ± 0.87 and 2.9 ± 2.3 log colony-forming units/g respectively, compared to 8.3 ± 0.9 log colony-forming units/g in control wounds (p < 0.001) and 6.9 ± 0.2 log colony-forming units/g in wounds treated with 4 mg/kg intravenous minocycline (p < 0.01). After 2 hours, topical minocycline reduced concentrations of the inflammatory cytokines interleukin-1β, interleukin-6, and tumor necrosis factor-α (p < 0.01), and inflammatory cell counts in wound tissue (p < 0.05). In noninfected wounds, topical minocycline significantly reduced interleukin-1β, interleukin-6, and inflammatory cell counts after 4 hours (p < 0.01). Matrix metalloproteinase-9 concentrations decreased after 1-hour treatment (p < 0.05). Keratinocyte and fibroblast in vitro functions were not adversely affected by 10 μg/ml minocycline or less. CONCLUSIONS:
|
Authors | Lauren Tracy Daly, David M Tsai, Mansher Singh, Kristo Nuutila, Raquel A Minasian, Cameron C Y Lee, Elizabeth Kiwanuka, Florian Hackl, Andrew B Onderdonk, Johan P E Junker, Elof Eriksson, Edward J Caterson |
Journal | Plastic and reconstructive surgery
(Plast Reconstr Surg)
Vol. 138
Issue 5
Pg. 856e-868e
(Nov 2016)
ISSN: 1529-4242 [Electronic] United States |
PMID | 27782997
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Anti-Bacterial Agents
- Biomarkers
- Minocycline
|
Topics |
- Administration, Topical
- Animals
- Anti-Bacterial Agents
(administration & dosage, pharmacology, therapeutic use)
- Biomarkers
(metabolism)
- Female
- Fibroblasts
(drug effects, metabolism)
- Humans
- Inflammation
(drug therapy, etiology, metabolism)
- Injections, Intravenous
- Keratinocytes
(drug effects, metabolism)
- Minocycline
(administration & dosage, pharmacology, therapeutic use)
- Random Allocation
- Staphylococcal Infections
(complications, drug therapy, metabolism)
- Swine
- Treatment Outcome
- Wound Infection
(complications, drug therapy, metabolism)
|